Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 1, 2011
- Ranbaxy Launches Generic Lipitor; Marketing Tie-up with Teva
December 1, 2011
- Sawai Aims at Sales of ¥10 Billion for Lipitor Generic
November 30, 2011
- Products Manufactured by BVL of the US Recalled in Response to EMA Recommendation
November 30, 2011
- US FDA Accepts NDA for Potential MS Treatment Carfilzomib: Ono
November 30, 2011
- Shionogi to Implement Organizational Change to Boost Domestic Sales Strength
November 29, 2011
- Pfizer Japan Obtains Approval for Additional Indication for Deep Mycosis Drug Diflucan
November 29, 2011
- AZ to Bolster Its Top Position in Breast Cancer Area
November 29, 2011
- Paraplatin Approved for Breast Cancer: BMKK
November 29, 2011
- Chugai Pharmaceutical to Introduce iPad2 to All MRs and MAs from Mid-January
November 29, 2011
- Mitsubishi Tanabe, Alfresa Obtain Approval for Additional Indication for Sleep Disorder Treatment Modiodal
November 29, 2011
- Pfizer Japan Launches 20 Generics with 10 APIs
November 29, 2011
- Kyowa Pharmaceutical Industry to Launch 2 Generic Drugs Made in India in 2012
November 28, 2011
- Nexium Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
November 28, 2011
- Novartis Files NDA for NVA237 for COPD in Japan
November 28, 2011
- M3 Survey Shows Doctors Want KOL Who Are “Easy to Understand” and Have “Extensive Experience”
November 28, 2011
- Iressa Approved for EGFR Mutation-Positive NSCLC: AZ
November 28, 2011
- Yakult Receives Approval for Changes to Dosage, Administration for Elplat as Post-Operative Therapy for Colorectal Cancer
November 28, 2011
- Chugai Pharmaceutical Obtains Approval for Additional Indication for Anticancer Agent Herceptin
November 28, 2011
- Additional Indication of Solar Keratosis Approved for Mochida Pharmaceutical's Beselna Cream
November 28, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…